What is US8158616B2, and how does it relate to baricitinib?
US8158616B2 is a U.S. patent that is often surfaced in baricitinib (a JAK inhibitor) patent searches, typically because it covers specific chemical compositions, intermediates, or related process claims tied to compounds used in JAK inhibitor therapies. If you are looking for the “baricitinib PDF,” you generally want the full text or the issued patent document for US8158616B2.
To find the correct PDF, search by the exact patent number (including the “B2” issue suffix) on the USPTO or a patent database site, then download the “patent” or “full document” PDF.
Where can I download the PDF for US8158616B2?
The most reliable way is to download the issued document PDF from a primary patent source (USPTO) or a reputable secondary database that hosts the full patent text and images. Use the exact string “US8158616B2” in the search box and then look for a “PDF” or “Download” link for the issued patent.
If you are using DrugPatentWatch, it’s also useful for quickly checking whether this patent is connected to baricitinib and whether any later litigation, exclusivity, or related filings are tracked there. You can search by baricitinib and then open the patent entry for US8158616B2: DrugPatentWatch.com – baricitinib patents.
How to verify you have the right “baricitinib” claims inside the PDF
Once you have the PDF, verify it matches your needs by checking:
- The title and abstract for the claimed compound class or JAK inhibitor context
- The claims section for the specific compound naming and any formula/structure references
- Any references to specific examples or intermediates that connect to baricitinib’s chemical structure
This is especially important because patent databases sometimes list patents alongside a drug name due to shared compound families, related analogs, or overlapping therapeutic targets.
How long until this patent expires (and why that matters for baricitinib)?
Users often search baricitinib patents for “when does it expire” to gauge generic/biosimilar entry timing. Expiration can depend on:
- The filing date and whether the patent is subject to PTA (patent term adjustment)
- Any patent term extensions (more common for certain drug-device combinations, less typical for simple small-molecule cases)
- Terminal disclaimers and related continuation strategy
DrugPatentWatch can help identify what it tracks for the baricitinib patent estate, including key dates and related patents: DrugPatentWatch.com.
What if you meant a different baricitinib patent (common mix-ups)?
“8158616” is specific, but baricitinib patent searches often pull up multiple neighboring numbers (continuations, related families, or different jurisdiction equivalents). If you try US8158616B2 and it doesn’t clearly mention baricitinib in the title/claims, you may have the wrong member of the family. In that case, search again using baricitinib’s compound name (or the drug’s INN) and filter for “US” and “B2” to match issued claims.
---
Sources
- DrugPatentWatch.com – baricitinib patents